Inventor · disambiguated record
Amy S. Johnson
Also filed as: JOHNSON AMY · JOHNSON AMY S
23 granted patents·22 pending applications·83 citations·filing 2014–2025
96Inventor score
Top patents by PatentIndex Score
45 records- 0198US12012445B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·4 cites·30 claims
- 0298US11958894B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0398US11732025B2Anti-VEGF protein compositions and methods for producing the sameREGENERAN PHARMACEUTICALS INC·Filed 2022·Granted Aug 22, 2023·11 cites·30 claims
- 0498US11548932B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Jan 10, 2023·8 cites·30 claims
- 0597US12012444B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2023·Granted Jun 18, 2024·2 cites·19 claims
- 0697US11753459B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·5 cites·30 claims
- 0797US11535663B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Dec 27, 2022·6 cites·10 claims
- 0897US11472861B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2021·Granted Oct 18, 2022·5 cites·26 claims
- 0997US11104715B2Methods for producing aflibercept in chemically defined media having reduced aflibercept variantsREGENERON PHARMA·Filed 2020·Granted Aug 31, 2021·5 cites·16 claims
- 1096US10927342B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2020·Granted Feb 23, 2021·23 cites·28 claims
- 1195US12331341B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2022·Granted Jun 17, 2025·2 cites·14 claims
- 1294US12338274B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 24, 2025·0 cites·30 claims
- 1394US12319728B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Granted Jun 3, 2025·0 cites·30 claims
- 1494US11505594B2Anti-VEGF protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2022·Granted Nov 22, 2022·1 cites·27 claims
- 1594US11332771B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2020·Granted May 17, 2022·3 cites·29 claims
- 1693US2024294606A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1790US12359166B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·29 claims
- 1890US12359165B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2024·Granted Jul 15, 2025·0 cites·30 claims
- 1988US12221619B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2023·Granted Feb 11, 2025·0 cites·30 claims
- 2088US2025340832A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2186US2025289868A1Anti-vegf protein compositions and methods for producing the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2285US2025327023A1Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2384US12163122B2Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variantsREGENERON PHARMA·Filed 2021·Granted Dec 10, 2024·1 cites·12 claims
- 2482US2023348532A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2582US2023331776A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2682US2023332084A1Bioreactor for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2782US2023287043A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2882US2023332201A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2982US2024010737A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3080US11312936B2Taurine supplemented cell culture medium and methods of useREGENERON PHARMA·Filed 2016·Granted Apr 26, 2022·1 cites·29 claims
- 3179US2022372436A1Serum-free cell culture mediumREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 3277US11970724B2Serum-free cell culture mediumREGENERON PHARMA·Filed 2021·Granted Apr 30, 2024·0 cites·6 claims
- 3374US2025066718A1Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variantsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3472US2021388408A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3572US2021388407A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3671US12291563B2Metabolically optimized cell cultureREGENERON PHARMA·Filed 2022·Granted May 6, 2025·0 cites·15 claims
- 3768US11390663B2Metabolically optimized cell cultureREGENERON PHARMA·Filed 2016·Granted Jul 19, 2022·1 cites·15 claims
- 3867US2020255880A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3966US2020131554A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4066US2014273095A1Serum-Free Cell Culture MediumREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4163US2019010531A1Cell culture process for making a glycoproteinREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 4257US2021087535A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4356US2016244725A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4454US2023063116A1Vegf mini-traps and method of use thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4532US2016244726A1Metabolically optimized cell cultureREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Amy S. Johnson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →